drugset / Trial / NCT06402630
A Phase 2 Placebo Controlled, Clinical Trial Designed to Assess the Efficacy, Safety and Dose Response Characterisation of STS01 for the Treatment of Mild-moderate Alopecia Areata (AA)
RandomizedParallel-groupQuadruple-blindTreatment
Summary
A Phase 2 double-blind, multi-site, placebo-controlled, parallel-group design to assess the efficacy, safety and dose-response characterisation of STS-01 for the treatment of mild- moderate alopecia areata.
Timeline
- Start
- 2022-03-23
- Primary completion
- 2024-04-01
- Completion
- 2024-04-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | STS01 | Unknown | 0.25 % | Topical |
| Subject | STS01 | Unknown | 0.5 % | Topical |
| Subject | STS01 | Unknown | 1 % | Topical |
| Subject | STS01 | Unknown | 2 % | Topical |